Compare THRY & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THRY | HURA |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 160.5M |
| IPO Year | 2020 | N/A |
| Metric | THRY | HURA |
|---|---|---|
| Price | $3.88 | $2.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $9.33 | ★ $9.50 |
| AVG Volume (30 Days) | 532.0K | ★ 581.0K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $785,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $0.41 |
| 52 Week High | $14.28 | $3.90 |
| Indicator | THRY | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 50.66 | 40.23 |
| Support Level | $3.27 | $1.82 |
| Resistance Level | $4.14 | $2.20 |
| Average True Range (ATR) | 0.25 | 0.15 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 48.77 | 1.00 |
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.